Related references
Note: Only part of the references are listed.Waldenstrom macroglobulinemia: 2021 update on diagnosis, risk stratification, and management
Morie A. Gertz
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Genomic Landscape of Waldenstrom Macroglobulinemia and Its Impact on Treatment Strategies
Steven P. Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study
Roger G. Owen et al.
LANCET HAEMATOLOGY (2020)
Liquid Biopsy as Novel Tool in Precision Medicine: Origins, Properties, Identification and Clinical Perspective of Cancer's Biomarkers
Diego Fernandez-Lazaro et al.
DIAGNOSTICS (2020)
The Digital MIQE Guidelines Update: Minimum Information for Publication of Quantitative Digital PCR Experiments for 2020
Jim F. Huggett et al.
CLINICAL CHEMISTRY (2020)
Zanubrutinib for the treatment of MYD88 wild-type Waldenstrom macroglobulinemia: a substudy of the phase 3 ASPEN trial
Meletios Dimopoulos et al.
BLOOD ADVANCES (2020)
A revised international prognostic score system for Waldenstrom's macroglobulinemia
Efstathios Kastritis et al.
LEUKEMIA (2019)
Progression Risk Stratification of Asymptomatic Waldenstrom Macroglobulinemia
Mark Bustoros et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E. Kastritis et al.
ANNALS OF ONCOLOGY (2018)
Highly sensitive MYD88(L265P) mutation detection by droplet digital polymerase chain reaction in Waldenstrom macroglobulinemia
Daniela Drandi et al.
HAEMATOLOGICA (2018)
Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies
Tina Bagratuni et al.
LEUKEMIA (2018)
Highly sensitive MYD88(L265P) mutation detection by droplet digital polymerase chain reaction in Waldenstrom macroglobulinemia
Daniela Drandi et al.
HAEMATOLOGICA (2018)
MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, andoverall survival
Steven P. Treon et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology
Raffaele Palmirotta et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenstrom Macroglobulinaemia
Joshua Gustine et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research
Terry K. Koo et al.
JOURNAL OF CHIROPRACTIC MEDICINE (2016)
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma A Comparison with Real-Time PCR
Daniela Drandi et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
MYD88 Mutations and Response to Ibrutinib in Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
Zachary R. Hunter et al.
BLOOD (2014)
Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia
Steven P. Treon et al.
BLOOD (2014)
Liquid Biopsies: Genotyping Circulating Tumor DNA
Luis A. Diaz et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Rapid detection of MYD88-L265P mutation by PCR-RFLP in B-cell lymphoproliferative disorders
N. Argentou et al.
LEUKEMIA (2014)
Multiparameter flow cytometry for the identification of the Waldenstrom's clone in IgM-MGUS and Waldenstrom's Macroglobulinemia: new criteria for differential diagnosis and risk stratification
B. Paiva et al.
LEUKEMIA (2014)
Detection of MYD88 L265P in peripheral blood of patients with Waldenstrom's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance
L. Xu et al.
LEUKEMIA (2014)
Detection of MYD88 L265P Mutation by Real-Time Allele-Specific Oligonucleotide Polymerase Chain Reaction
Cristina Jimenez et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2014)
MYD88 L265P mutation in Waldenstrom macroglobulinemia
Stephanie Poulain et al.
BLOOD (2013)
Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms
Marzia Varettoni et al.
BLOOD (2013)
MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction
Lian Xu et al.
BLOOD (2013)
Digital PCR as a Novel Technology and Its Potential Implications for Molecular Diagnostics
Jim F. Huggett et al.
CLINICAL CHEMISTRY (2013)
MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom's macroglobulinemia
C. Jimenez et al.
LEUKEMIA (2013)
MYD88 L265P Somatic Mutation in Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
IgM Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Waldenstrom's Macroglobulinemia (SWM)
Robert A. Kyle et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Monoclonal gammopathies of undetermined significance: a review
RA Kyle et al.
IMMUNOLOGICAL REVIEWS (2003)
Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia
RG Owen et al.
SEMINARS IN ONCOLOGY (2003)
IgM paraproteinaemia: disease associations and laboratory features
PJ Roberts-Thomson et al.
PATHOLOGY (2002)
Share Paper
